. "563018" . "Biochemical Pharmacology" . . . "-" . . "Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way" . . "841;854" . "Anthosen, M. W." . "Rubic, T." . "Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way"@en . "PPARg, CD36, LDL"@en . . . "67" . "Z(AV0Z5052915)" . "1"^^ . "And\u011Bra, Ladislav" . "Enzymaticky modifikovan\u00FD lipoprotein o n\u00EDzk\u00E9 hustot\u011B (LDL) zvy\u0161uje expresi CD36 v m\u00E1lo diferencovan\u00FDch monocytech cestou z\u00E1vislou na receptoru gama aktivovan\u00E9m peroxizomov\u00FDch prolifer\u00E1torem"@cs . "Trottman, M." . "Weber, C." . "Peroxisome proliferator-activated receptor-g (PPARg) has been suggested to upregulate CD36. Since free oxidized polyunsaturated fatty acids are PPARg ligands, we studied the effects of LDL modified by the simultaneous action of sPLA2 and 15-lipoxygenase (15LO) on CD36 expression and PPARg activation in monocytic cells. Exposure of MM6 cells, which do not express CD36 or other scavenger receptors, to such enzymatically modified LDL (enzLDL) resulted in upregulation of CD36 surface protein and mRNA expression. Similar effects were observed with free 13-hydroperoxyoctadecadienoic acid but not its esterified counterpart. Less pronounced effects were observed with LDL modified by 15LO alone. Upregulation of CD36 was inversely correlated to the state of cell differentiation, as showed by lower response to enzLDL of the scavenger receptor-expressing MM6-sr and THP1 cells. Importantly, LDL modified by sPLA2 and 15LO did not efficiently induce upregulation CD36 in PPARg-deficient macrophage-..."@en . "Jostarndt, K." . . "Neu\u017Eil, J." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Kuhn, H." . "0006-2952" . . "[EA8B9194DA59]" . "11"^^ . "Gellert, N." . "RIV/68378050:_____/04:00105319!RIV/2005/AV0/A23005/N" . . . "RIV/68378050:_____/04:00105319" . "Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way" . . "Johansen, B." . "Hrboticky, N." . "P\u0159edpokl\u00E1d\u00E1 se, \u017Ee receptor gama aktivovan\u00FD peroxizomov\u00FDch prolifer\u00E1torem (PPARg) zvy\u0161uje expresi CD36. Jeliko\u017E voln\u00E9 oxidovan\u00E9 poly-nenasycen\u00E9 mastn\u00E9 kyseliny jsou ligandy PPARg, studovali jsme \u00FA\u010Dinky LDL modifikovan\u00E9ho sou\u010Dasn\u00FDm p\u016Fsoben\u00EDm sPLA2 a 15-lipoxygen\u00E1zy (15LO) na expresi CD36 a aktivaci PPARg v monocytech. Vystaven\u00ED bun\u011Bk MM6, kter\u00E9 neexprimuj\u00ED CD36 ani jin\u00E9 zachyt\u00E1vac\u00ED receptory, takto enzymaticky modifikovan\u00E9mu LDL (enzLDL) vedlo ke zv\u00FD\u0161en\u00ED exprese povrchov\u00E9ho proteinu a mRNA CD36. Podobn\u00E9 \u00FA\u010Dinky byly pozorov\u00E1ny u voln\u00E9 13-hydroperoxyoktadekadienov\u00E9 kyseliny, ale ne u jej\u00EDho esteru. M\u00E9n\u011B v\u00FDrazn\u00E9 \u00FA\u010Dinky byly pozorov\u00E1ny u LDL modifikovan\u00E9ho samotnou 15LO. Zv\u00FD\u0161en\u00ED exprese CD36 bylo nep\u0159\u00EDmo \u00FAm\u011Brn\u00E9 stavu bun\u011B\u010Dn\u00E9 diferenciace, jak uk\u00E1zala ni\u017E\u0161\u00ED odpov\u011B\u010F bun\u011Bk MM6-sr a THP1, exprimuj\u00EDc\u00EDch zachyt\u00E1vac\u00ED receptor, na enzLDL. Je d\u016Fle\u017Eit\u00E9, \u017Ee LDL modifikovan\u00FD sPLA2 a 15LO nevyvol\u00E1val \u00FA\u010Dinn\u00E9 zv\u00FD\u0161en\u00ED exprese v embryon\u00E1ln\u00EDch kmenov\u00FDch bu\u0148k\u00E1ch diferencovan\u00FDch makrof\u00E1gy a postr\u00E1daj\u00EDc\u00EDch P..."@cs . . "Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way"@en . "Peroxisome proliferator-activated receptor-g (PPARg) has been suggested to upregulate CD36. Since free oxidized polyunsaturated fatty acids are PPARg ligands, we studied the effects of LDL modified by the simultaneous action of sPLA2 and 15-lipoxygenase (15LO) on CD36 expression and PPARg activation in monocytic cells. Exposure of MM6 cells, which do not express CD36 or other scavenger receptors, to such enzymatically modified LDL (enzLDL) resulted in upregulation of CD36 surface protein and mRNA expression. Similar effects were observed with free 13-hydroperoxyoctadecadienoic acid but not its esterified counterpart. Less pronounced effects were observed with LDL modified by 15LO alone. Upregulation of CD36 was inversely correlated to the state of cell differentiation, as showed by lower response to enzLDL of the scavenger receptor-expressing MM6-sr and THP1 cells. Importantly, LDL modified by sPLA2 and 15LO did not efficiently induce upregulation CD36 in PPARg-deficient macrophage-..." . "Enzymaticky modifikovan\u00FD lipoprotein o n\u00EDzk\u00E9 hustot\u011B (LDL) zvy\u0161uje expresi CD36 v m\u00E1lo diferencovan\u00FDch monocytech cestou z\u00E1vislou na receptoru gama aktivovan\u00E9m peroxizomov\u00FDch prolifer\u00E1torem"@cs . "14"^^ . . .